MA46359A - Protéines de liaison à l'antigène à viscosité faible et leurs procédés de préparation - Google Patents

Protéines de liaison à l'antigène à viscosité faible et leurs procédés de préparation

Info

Publication number
MA46359A
MA46359A MA046359A MA46359A MA46359A MA 46359 A MA46359 A MA 46359A MA 046359 A MA046359 A MA 046359A MA 46359 A MA46359 A MA 46359A MA 46359 A MA46359 A MA 46359A
Authority
MA
Morocco
Prior art keywords
antigen binding
low viscosity
binding proteins
preparation processes
processes
Prior art date
Application number
MA046359A
Other languages
English (en)
Inventor
Neeraj Jagdish Agrawal
Pavel Bondarenko
Joon Huh
Andrew Nichols
Da Ren
Richard Smith
Riki Stevenson
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA46359A publication Critical patent/MA46359A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N11/00—Investigating flow properties of materials, e.g. viscosity, plasticity; Analysing materials by determining flow properties
    • G01N11/10—Investigating flow properties of materials, e.g. viscosity, plasticity; Analysing materials by determining flow properties by moving a body within the material
    • G01N11/14—Investigating flow properties of materials, e.g. viscosity, plasticity; Analysing materials by determining flow properties by moving a body within the material by using rotary bodies, e.g. vane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA046359A 2016-09-29 2017-09-28 Protéines de liaison à l'antigène à viscosité faible et leurs procédés de préparation MA46359A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662401770P 2016-09-29 2016-09-29
US201662430773P 2016-12-06 2016-12-06
US201762546469P 2017-08-16 2017-08-16

Publications (1)

Publication Number Publication Date
MA46359A true MA46359A (fr) 2019-08-07

Family

ID=60245172

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046359A MA46359A (fr) 2016-09-29 2017-09-28 Protéines de liaison à l'antigène à viscosité faible et leurs procédés de préparation

Country Status (14)

Country Link
US (2) US11059908B2 (fr)
EP (1) EP3519439A2 (fr)
JP (3) JP2019532063A (fr)
KR (2) KR102551269B1 (fr)
CN (1) CN110036031A (fr)
AU (1) AU2017336673A1 (fr)
CA (1) CA3038909A1 (fr)
CL (2) CL2019000835A1 (fr)
IL (2) IL307684A (fr)
MA (1) MA46359A (fr)
MX (1) MX2019003727A (fr)
SG (1) SG10201912565QA (fr)
WO (1) WO2018064307A2 (fr)
ZA (1) ZA201902297B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323081B2 (en) * 2011-07-06 2019-06-18 Genmag A/S Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains
PT2953634T (pt) 2013-02-07 2021-09-02 Massachusetts Gen Hospital Métodos de expansão ou depleção das células t reguladoras
WO2016010927A1 (fr) * 2014-07-14 2016-01-21 Amgen Inc. Formulations d'anticorps cristallins
AU2015335743B2 (en) 2014-10-23 2020-12-24 Amgen Inc. Reducing viscosity of pharmaceutical formulations
CN109476745B (zh) 2016-05-13 2023-11-24 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
JP7377596B2 (ja) * 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
KR20190132215A (ko) 2018-05-18 2019-11-27 서울반도체 주식회사 발광 다이오드, 발광 다이오드 모듈 및 그것을 갖는 표시 장치
CA3109954A1 (fr) * 2018-08-20 2020-02-27 The General Hospital Corporation Polypeptides antagonistes de la superfamille des recepteurs au facteur de necrose tumorale
WO2020185763A1 (fr) * 2019-03-11 2020-09-17 Memorial Sloan Kettering Cancer Center Anticorps cd22 et leurs procédés d'utilisation
GB2590642B (en) * 2019-12-20 2024-02-14 Kymab Ltd Improved lambda antibodies
EP3990499A4 (fr) * 2019-06-26 2023-07-05 Amunix Pharmaceuticals, Inc. Fragments de liaison à l'antigène egfr et compositions les comprenant
WO2021202013A1 (fr) * 2020-03-30 2021-10-07 Crystal Bioscience Inc. Anticorps anti-gipr et ses procédés d'utilisation
CN113512116B (zh) * 2020-04-10 2022-09-20 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
WO2022011264A2 (fr) * 2020-07-10 2022-01-13 The Wistar Institute Of Anatomy And Biology Constructions d'anticorps d'adn à utiliser contre un rotavirus

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
AU2012229251A1 (en) 2011-03-11 2013-09-12 Amgen Inc. Method of correlated mutational analysis to improve therapeutic antibodies
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
HUE056217T2 (hu) * 2012-07-13 2022-02-28 Roche Glycart Ag Bispecifikus anti-VEGF/anti-ANG-2 antitestek és ezek alkalmazása szemészeti érbetegségek kezelésében
EP2992010B1 (fr) * 2013-04-29 2021-03-24 F.Hoffmann-La Roche Ag Anticorps asymétrique modifié de liaison fc-receptor et procédés d'utilisation
EP3026061A1 (fr) * 2014-11-26 2016-06-01 Novo Nordisk A/S Mutagenèse dirigée sur site d'anticorps trem-1 pour diminuer la viscosite
NZ743474A (en) * 2015-12-23 2023-03-31 Amgen Inc Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists

Also Published As

Publication number Publication date
EP3519439A2 (fr) 2019-08-07
KR20190053271A (ko) 2019-05-17
JP2023178409A (ja) 2023-12-14
JP2019532063A (ja) 2019-11-07
IL265692A (en) 2019-05-30
CN110036031A (zh) 2019-07-19
CL2019000835A1 (es) 2019-05-31
ZA201902297B (en) 2019-12-18
US11059908B2 (en) 2021-07-13
WO2018064307A2 (fr) 2018-04-05
WO2018064307A4 (fr) 2018-09-27
CA3038909A1 (fr) 2018-04-05
WO2018064307A3 (fr) 2018-07-05
AU2017336673A1 (en) 2019-04-18
KR20230107696A (ko) 2023-07-17
US11993663B2 (en) 2024-05-28
MX2019003727A (es) 2019-08-05
JP2022081654A (ja) 2022-05-31
CL2021003596A1 (es) 2022-08-19
US20190233543A1 (en) 2019-08-01
IL265692B2 (en) 2024-03-01
IL265692B1 (en) 2023-11-01
IL307684A (en) 2023-12-01
US20210371544A1 (en) 2021-12-02
SG10201912565QA (en) 2020-02-27
KR102551269B1 (ko) 2023-07-05

Similar Documents

Publication Publication Date Title
MA46359A (fr) Protéines de liaison à l'antigène à viscosité faible et leurs procédés de préparation
MA52273A (fr) Protéines de liaison à un antigène anti-trem2 et leurs utilisations
MA46917A (fr) Anticorps anti-met, molécules de liaison à un antigène bispécifique se liant à met, et leurs procédés d'utilisation
MA43576A (fr) Anticorps anti-lag3 et fragments de fixation à l'antigène
MA49457A (fr) Molécules d'anticorps se liant à cd73 et leurs utilisations
MA42808A (fr) Anticorps de liaison à l'il-8 et leurs utilisations
MA50753A (fr) Compositions d'acide nucléique-polypeptide et utilisations de celles-ci
SG11202001163UA (en) Molecules having one hydrophobic group and two identical hydrophilic ionic groups and compositions thereof
MA42446A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
MA54513A (fr) Molécules de liaison à l'antigène cd28 agonistes de ciblage de tumeurs
MA50949A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA44885A (fr) Protéines de liaison bispécifiques et leurs utilisations
MA47113A (fr) Protéines de liaison à l'antigène anti- neuropiline et leurs méthodés d'utilisation
MA46529A (fr) Anticorps anti-lag-3 et leurs procédés d'utilisation
MA55347A (fr) Anticorps anti-lag3 et fragments de fixation à l'antigène
WO2017136820A3 (fr) Technologie fit-immunoglobuline et ses utilisations
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA42821A (fr) Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci
MA41414A (fr) Protéines de liaison agonistes d' icos
MA41558A (fr) Compositions d'allergènes mélangés et leurs procédés d'utilisation
MA42971A (fr) Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
MA42819A (fr) Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
MA55825A (fr) Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation
MA43308A (fr) Molécules d'anticorps se liant à april et leurs utilisations